| Item Type | Name |
|
Concept
|
Interleukin-2
|
|
Concept
|
Interleukin-12
|
|
Concept
|
Receptors, Interleukin-17
|
|
Concept
|
Interleukin-23
|
|
Concept
|
Interleukin-23 Subunit p19
|
|
Concept
|
Interleukin-17
|
|
Academic Article
|
Differential abilities of central nervous system resident endothelial cells and astrocytes to serve as inducible antigen-presenting cells.
|
|
Academic Article
|
Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial.
|
|
Academic Article
|
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).
|
|
Academic Article
|
A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis.
|
|
Academic Article
|
Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis.
|
|
Academic Article
|
Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial.
|
|
Academic Article
|
Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials.
|
|
Academic Article
|
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.
|
|
Academic Article
|
Rationale and early clinical data on IL-17 blockade in psoriasis.
|
|
Academic Article
|
Unmet needs in the treatment of psoriasis.
|
|
Academic Article
|
A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.
|
|
Academic Article
|
New and emerging therapies in psoriasis.
|
|
Academic Article
|
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
|
|
Academic Article
|
Translating the Science of Psoriasis.
|
|
Academic Article
|
In vivo gene therapy with interleukin-12 inhibits primary vascular tumor growth and induces apoptosis in a mouse model.
|
|
Academic Article
|
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
|
|
Academic Article
|
Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis.
|
|
Academic Article
|
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
|
|
Academic Article
|
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
|
|
Academic Article
|
IL-23 inhibitors for moderate-to-severe psoriasis.
|
|
Academic Article
|
Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis.
|
|
Academic Article
|
Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study.
|
|
Academic Article
|
Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis.
|
|
Academic Article
|
Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study.
|
|
Academic Article
|
Risankizumab in moderate-to-severe plaque psoriasis.
|
|
Academic Article
|
Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2.
|
|
Academic Article
|
Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis.
|
|
Academic Article
|
Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials.
|
|
Academic Article
|
Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis.
|
|
Academic Article
|
Anti-IL 23 biologics for the treatment of plaque psoriasis.
|
|
Academic Article
|
Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study.
|
|
Academic Article
|
Sequencing of Targeted Therapy in Psoriasis: Does it Matter?
|